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The human immunodeficiency virus type 2 (HIV-2) strain LAV-2/B is able to infect a variety of human cell
lines via a CD4-independent pathway. We have used the glycosylation inhibitors tunicamycin, swainsonine, and
deoxymannojirimycin to further characterize this putative alternative receptor for HIV-2 (LAV-2/B). These
antibiotics resulted in an increase (5- to 30-fold) in the susceptibility of a variety of CD42 human cell lines to
infection by LAV-2/B (RD, HeLa, HT29, Rsb, Heb7a, Hos, and Daudi). Several nonprimate cell lines (mink
Mv-1-lu, rabbit SIRC, hamster a23, mouse NIH 3T3, cat CCC, and rat HSN) remained resistant to infection
by LAV-2/B after treatment with glycosylation inhibitors, suggesting that they do not express the HIV-2
CD4-independent receptor. Two of these nonprimate cell lines are readily infected by HIV-2 when they express
CD4 (Mv-1-lu and CCC). Treatment of human cells with neuraminidase had no effect on subsequent infection
by LAV-2/B, suggesting that the increase in susceptibility to infection of deglycosylated cells is not due to a
change in the electrostatic charge of the cell surface. Treatment of RD CD42 cells and HeLa CD41 cells with
a variety of proteases resulted in a 75 to 90% decrease in infection by LAV-2/B when compared with untreated
cells. Taken together, all these data suggest that HIV-2 can utilize a membrane glycoprotein other than CD4
to attach and fuse with a variety of human cells.
The CD4 molecule is the principal cellular receptor for the
human and simian immunodeficiency viruses (HIV-1, HIV-2,
and SIV) (15, 24, 40). However, attachment of HIV or SIV to
CD4 on the cell membrane is not always sufficient for infection.
Several examples exist in which HIV or SIV binding to CD41
human or nonhuman cells does not lead to membrane fusion
or infection (1, 2, 6, 8, 28, 29). The implications of these
experiments are that cell surface components other than CD4
are necessary for HIV entry. Furthermore, many cell lines of
nervous system, liver, and fibroblast origin do not express CD4
but can be infected, albeit less efficiently, with one or more
strains of HIV-1 (7, 10, 16, 19, 20, 45). It has been reported
that a selected strain of HIV-2 (LAV-2/B) can efficiently direct
cell-to-cell fusion and infection of certain CD4-negative hu-
man cell lines (9). Infection of CD4-negative cells by other
HIV-2 strains was induced or greatly enhanced by the presence
of soluble CD4 (sCD4). The CD4 molecule therefore appears
to induce conformational changes in the virus envelope glyco-
proteins (41) which may be necessary for fusion of viral and
cellular membranes.
Here we report on the biochemical characterization of the
receptor involved in HIV-2 CD4-independent entry into cells.
These data show that inhibition of complex glycan synthesis on
membrane glycoproteins increases the rate of infection of cer-
tain human cells by HIV-2 via the CD4-independent receptor.
Steric blocking of virus-binding sites on the receptor by com-
plex glycans and different glycosylation patterns among human
cell lines may account for the selective tropism pattern of
LAV-2/B on CD4-negative cells. Furthermore, the protease
sensitivity of CD4-negative cells points to the presence of a
membrane protein in the CD4-independent entry pathway of
HIV-2.
MATERIALS AND METHODS
Cells. The human T-cell line, H9 (38), and B-cell line, Daudi (37), were both
maintained as suspension cultures in RPMI 1640 medium (Gibco), supple-
mented with 10% (vol/vol) fetal calf serum (FCS), 60 mg of penicillin per ml, and
100 mg of streptomycin per ml. The human rhabdomyosarcoma cell line RD
(TE671 subline) (43), the human carcinoma lines HeLa, Heb7a, HT-29, Rsb, and
SCL1, the osteosarcoma cell line HOS (6, 8, 9), the fibrosarcoma cell line
HT1080 (39), the human fibroblast cell line WI38 (6) and nonprimate fibroblast
cell lines (i) rabbit corneal cell line SIRC (27), (ii) Chinese hamster lung fibro-
blastoid cell line a23 (46), (iii) mouse cell line NIH 3T3 (29, 30), (iv) cat kidney
cell line CCC (12), (v) rat sarcoma cell line HSN (13), and (vi) mink lung cell line
Mv-1-lu (23) were all maintained as monolayers in Dulbecco’s modified Eagle’s
medium (Gibco) supplemented with 4% (vol/vol) FCS, 60 mg of penicillin per ml,
and 100 mg of streptomycin per ml. HeLa CD41 (28) cells were maintained in the
same medium supplemented with 1 mg of geneticin (Gibco) per ml.
Viruses. The HIV-2 strain LAV-2/B (9) was derived from C8166 cells chron-
ically infected with LAV-2ROD (11). The HIV-2 strain CBL-22 has been de-
scribed previously (9).
Antibodies. The monoclonal antibody to the V1 domain of human CD4 (22)
was supplied by the Medical Research Council AIDS Reagent Programme (re-
pository reference ADP318). The neutralizing monoclonal antibody to LAV-2/B
SU glycoprotein, 8e, and the pooled rat monoclonal antibodies against LAV-2/B
envelope used for immunostaining were gifts from A´ine McKnight (29a).
Treatment of cells with glycosylation inhibitors. Cells were seeded at 105 cells
per ml on 24-well trays and grown for 24 h at 378C; then, the medium was
replaced with medium containing 0.1 mg of tunicamycin per ml, 0.1 mM swain-
sonine, or 1 mM 1-deoxymannojirimycin (Sigma). The cultures were allowed to
grow for a further 24 h, and then the medium was removed and fresh medium
containing serially diluted virus was added. The virus was allowed to adsorb for
5 h at 378C, when it was replaced with more fresh medium. After overnight
incubation, 1 mg of azidothymidine (AZT; Sigma) per ml was added; the infected
cells were immunostained after a further 3 days of incubation.
Treatment of virus with monoclonal antibodies and sCD4. LAV-2/B was
neutralized with the rat MAb 8e (final concentration, 1 mg/ml) for 1 h at 378C
prior to addition to cells. In experiments with sCD4 (kindly provided by Ray
Sweet, SmithKline Beecham), virus was incubated for 1 h with 10 mg of sCD4 per
ml at 378C prior to addition to cells. Cells were treated with anti-CD4 monoclo-
nal antibody (5 mg/ml) for 24 h prior to infection with virus.
Neuraminidase treatment of cells. Cells were seeded at 105 cells per ml on
24-well plates and grown for 24 h at 378C. The cells were washed twice in
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complete phosphate-buffered saline (cPBS)–0.05% FCS, and then 200 ml of
bacterial neuraminidase solution (0.2 U/ml in cPBS–0.05% FCS) from either
Salmonella typhimurium (Sigma) or Vibrio cholerae (Boehringer Mannheim) or
cPBS–0.05% FCS alone was added to the wells. After incubation at 378C for 1 h,
the cells were washed three times with cPBS. LAV-2/B was titrated on the cells
and allowed to adsorb for 2 h at 48C (incubation at this temperature was used to
allow virus attachment but prevent cells from regenerating glycoproteins con-
taining terminal sialic acid residues). After overnight incubation, AZT (1 mg/ml)
was added; the infected cells were immunostained after a further 3 days of
incubation.
An agglutination assay was used to assess the cleavage of terminal sialic acid
residues by the bacterial neuraminidase. Approximately 106 cells were treated
with neuraminidase (0.2 U/ml in cPBS–0.05% FCS) and then aliquoted onto
round-bottom 96-well plates (105 cells per well). Lectin from Limulus
polyphemus (Sigma) was titrated (fourfold serial dilutions in cPBS–100 mM
CaCl2) onto the cells, and the plates were incubated for 30 min at 378C.
Protease treatment of cells. Cells were removed with Versene (0.02% [wt/vol]
in PBS), washed once with cPBS–0.1% (wt/vol) EDTA, and incubated with
trypsin (1 mg/ml; Sigma), a-chymotrypsin (0.02 mg/ml; Sigma), or bromelain
(0.02 mg/ml; Sigma) diluted in cPBS–0.1% (wt/vol) EDTA (2 3 106 cells per ml)
for 10 min at 378C. Soybean trypsin inhibitor (type II-S; Sigma), chymotrypsin-
trypsin inhibitor (Sigma), or bromelain inhibitor (Sigma) was added at 1 mg/ml,
and the cells were washed three times with cPBS–0.1% (wt/vol) EDTA at 48C.
The cells were finally resuspended in complete medium and plated onto 24-well
trays (200 ml per well; 4 3 105 cells). LAV-2/B was titrated onto the cells and
allowed to adsorb at 48C for 2 h (incubation at this temperature was used to keep
regeneration of cleaved surface proteins to a minimum). At the end of this
period, medium containing unbound virus was removed and added to untreated
cells to determine virus viability. After overnight incubation, AZT (1 mg/ml) was
added; the infected cells were immunostained after a further 3 days of incuba-
tion.
Cell-free virus infections. Virus supernatant stocks were serially diluted in
fivefold steps and added in 250-ml amounts to appropriate cell types in 24-well
trays. Unless otherwise stated, the virus was allowed to adsorb for 5 h at 378C
before unbound virus was removed and replaced with appropriate medium. After
overnight incubation, AZT (1 mg/ml) was added; the infected cells were immu-
nostained after a further 3 to 5 days of incubation.
Immunostaining HIV-2-infected cells. Infection assays were typically per-
formed in 24-well tissue culture trays. Three days after infection, the medium was
removed and the cells were washed twice in PBS before being fixed with a 50:50
mixture of methanol-acetone at2408C for 2 min. After removal of the methanol-
acetone, the cells were washed once with PBS followed by PBS containing 1%
(vol/vol) FCS. The primary antibody (pooled rat monoclonal antibodies against
LAV-2/B envelope; 250 ml per well, diluted 1:50 in PBS–1% FCS) was added to
the fixed cells, allowed to bind for 1 h at room temperature, and then washed
twice in PBS–1% FCS. Goat anti-rat immunoglobulin G–b-galactosidase conju-
gate (Sera-labs) at a 1:600 dilution (in PBS–1% FCS) was added for 1 h at room
temperature, and the mixture was washed twice in serum-free PBS. Approxi-
mately 500 ml of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) sub-
strate (0.5 mg/ml) in PBS containing 3 mM potassium ferricyanide, 3 mM
potassium ferrocyanide, and 1 mM magnesium chloride was added to each well.
Infected cells stained blue within 1 to 2 h of the addition of substrate.
RESULTS
Throughout this study, an immunostaining procedure (9)
has been used to assess the infection and replication of HIV-2
in a variety of CD4-negative cells pretreated with glycosylation
inhibitors, protease, or bacterial neuraminidase. The second-
ary antibody in this assay is conjugated to b-galactosidase,
which stains infected cells blue upon addition of the substrate
(X-Gal). The immunostaining procedure proved very specific
for HIV-2-infected cells, with no background staining or stain-
ing of uninfected cells being observed (Fig. 1). In all experi-
ments, virus was titrated onto the cells by fivefold serial dilu-
tion steps, and the apparent titers were determined by
counting the number of foci of infection. To prevent the pos-
sibility of secondary infections increasing the observed virus
titer, the reverse transcriptase inhibitor AZT was included in
the incubation medium. Titers have been expressed as focus-
forming units per milliliter.
Figure 1 shows the immunostaining of a number of LAV-2/
B-infected human cells. Infection of RD cells and HeLa CD41
cells results in significant cell-to-cell fusion with formation of
large syncytia. LAV-2/B infection of HeLa and HOS cells
produced a majority of singly infected cells and a very few
small syncytia, whereas infection of HT-29, Rsb, and Heb7a
cells produced only singly infected cells and no cell-to-cell
fusion (Table 1).
Treatment of a variety of human cells with glycosylation
inhibitors increases the susceptibility to infection by HIV-2 via
the CD4-independent pathway.We have tested the infectibility
of a panel of CD4-negative human cells by HIV-2 after treat-
ment with the glycosylation inhibitors tunicamycin, swainso-
nine, and 1-deoxymannojirimycin. Tunicamycin inhibits the
first reaction in the lipid-saccharide pathway (synthesis of N-
acetylglucosaminyl pyrophosphoryl polyisoprenol), blocking
N-linked glycosylation completely (44). The antibiotics 1-de-
oxymannojirimycin and swainsonine inhibit the mannose-trim-
ming enzymes mannosidase IA/B and mannosidase II, respec-
tively, and therefore prevent the subsequent synthesis of
complex glycan structures (18). Tunicamycin was observed to
inhibit cell growth in comparison with untreated cells, whereas
swainsonine and 1-deoxymannojirimycin had little effect. Tu-
nicamycin treatment of certain CD4-negative human cells
(RD, HeLa, HOS, Rsb, HT-29, and Heb7a) increased the
apparent titer of LAV-2/B by between 5- and 30-fold (Fig. 2).
Conversely, tunicamycin pretreatment of RD or HeLa cells did
not remove the block to infection by HIV-1 (IIIb) (results not
shown). Pretreatment of human cells with the antibiotics
swainsonine and 1-deoxymannojirimycin resulted in a smaller
increase in the apparent titer of LAV-2/B of up to fivefold (Fig.
2). However, none of the three antibiotics used had any effect
on the infectability of HeLa CD41 cells by LAV-2/B, although
infection by HIV-1 (IIIb) was decreased approximately four-
fold after pretreatment of the cells with tunicamycin. This
observation is consistant with down regulation of the surface
expression of CD4 as a result of selective degradation of par-
tially glycosylated molecules after tunicamycin treatment (26).
The effective increase in infection of tunicamycin-treated
HeLa cells by LAV-2/B via the CD4-independent receptor
(and presumably HeLa CD41 cells) apparently cancels the
effect of the down regulation of CD4.
The CD4-independent infection of RD cells by strain
CBL-22 is increased 30-fold after treatment of the cells with
tunicamycin. Clapham et al. (9) have shown that another strain
of HIV-2 (CBL-22) can fuse RD cells in a CD4-independent
manner. We have determined the titer of CBL-22 on a variety
of human cells treated with tunicamycin. The results in Table
2 show that tunicamycin pretreatment of RD cells increases the
titer of CBL-22 by 30-fold. This is in contrast to the low rate of
infection of HeLa, Rsb, and Heb7a cells by CBL-22, which was
not enhanced after treatment with tunicamycin. CBL-22
showed no infection of five other human cell lines (HT29,
HOS, SCL1, HT1080, and WI38).
sCD4 further enhances the susceptibility of tunicamycin-
treated CD4-negative cells to infection by HIV-2. It has been
reported previously that pretreatment of several HIV-2 strains
with sCD4 enhances the fusion of CD4-negative RD (TE671)
cells (9). Figure 3 shows that infection of tunicamycin-treated
RD cells is further enhanced in the presence of sCD4 (10
mg/ml). This is most dramatically indicated when comparing
the infection of untreated RD cells by LAV-2ROD with the
infection of tunicamycin-treated RD cells by LAV-2ROD in the
presence of sCD4 (50-fold enhancement). Conversely, infec-
tion of HeLa CD41 cells by both LAV-2/B and LAV-2ROD is
inhibited in the presence of sCD4. This inhibitory effect is
partially alleviated when the cells are pretreated with tunica-
mycin, presumably because this increases the availability of the
CD4-independent receptor as a route for infection.
The increased sensitivity to infection by HIV-2 is a receptor-
specific process. To test the possibility that tunicamycin acts in
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FIG. 1. Immunostaining of CD4-negative human cells after infection with LAV-2/B. Cells were stained as described in Materials and Methods, with infected cells
appearing black in the images. (a) RD (TE671); (b) HeLa; (c) HeLa CD41; (d) HOS; (e) Heb7a; (f) Rsb; (g) HT-29; (h) SCL1. The human cells SCL1 (panel h), WI38,
and HT1080 and the nonprimate cells SIRC, CCC, HSN, Mv-1-lu, NIH 3T3, and a23 were all uninfected with LAV-2/B. Pretreatment of RD or HeLa cells with
tunicamycin did not allow infection by HIV-1 (IIIb).
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some nonspecific manner to promote infection of CD4-nega-
tive cells by HIV-2, we attempted to infect various tunicamy-
cin-treated nonprimate cells with LAV-2/B. None of the non-
primate cells were infected by LAV-2/B after treatment with
tunicamycin (Table 1), although some will allow LAV-2/B in-
fection and replication when human CD4 is expressed on the
cell surface (CCC and Mv-1-lu [29]). These data indicate that
the HIV-2 CD4-independent receptor is not expressed on the
nonprimate cells tested (and also certain human cells, e.g.,
HT1080, WI38, and SCL1 [Table 1]) in a form recognizable by
LAV-2/B and that the effect of tunicamycin on other human
cells is specific. Furthermore, LAV-2/B infection of tunicamy-
cin-treated CD4-negative cells is completely blocked by the
neutralizing monoclonal antibody 8e (Fig. 4). This monoclonal
antibody specifically blocks entry of LAV-2/B into cells via the
CD4-independent pathway (29a). Figure 4 shows that 8e does
not block entry of LAV-2/B into HeLa CD41 cells except when
they have been pretreated with tunicamycin. This may be ex-
plained by the observation that tunicamycin can lead to down
regulation of the expression of CD4 on the cell membrane, as
a result of a selective degradation of unglycosylated CD4 mol-
ecules (26). A monoclonal antibody against human CD4 does
not block infection of CD4-negative cells, whether or not they
have been pretreated with tunicamycin. However, anti-CD4
does block infection of untreated HeLa CD41 cells. Pretreat-
ment of HeLa CD41 cells with tunicamycin removes the sub-
sequent block to infection by anti-CD4, since LAV-2/B is able
to utilize the CD4-independent receptor to gain entry.
The low rate of infection of many human cell types is not due
to any secreted inhibitory factors. It has been reported that
CHO-K1 cells (31) secrete a soluble factor (possibly an endo-
genous retroviral Env protein) which is responsible for block-
ing infection by murine leukemia virus and amphotrophic
pseudotypes of gibbon ape leukemia virus. We have investi-
gated the possibility that the low level of HIV-2 infection of
some human cells is due to a secreted soluble inhibitory factor
rather than to the heterogeneity of glycosylation of the recep-
tor on different cell types. Serial dilutions of LAV-2/B were
incubated for 1 h in either HeLa cell conditioned medium or
untreated medium and then added to RD cells on 24-well trays
which had also been incubated for 1 h with HeLa cell condi-
tioned medium or untreated medium. The apparent titer of
LAV-2/B was not altered by preincubation of virus or cells in
HeLa cell conditioned medium, suggesting that HeLa cells do
not secrete any factors which interfere with HIV-2 infection.
Removal of terminal sialic acid residues from cell surface
glycoproteins has no effect on infection by HIV-2. Sialic acid on
the surface of RD, HeLa, and HeLa CD41 cells is not required
for the attachment of LAV-2/B, since cleavage of terminal
sialic acids by neuraminidase from V. cholerae or S. typhi-
murium had no significant effect on infection (Fig. 5a). Neur-
aminadases from V. cholerae and S. typhimurium have prefer-
ences for cleaving a-2,6- and a-2,3-linked sialic acid residues,
respectively (21).
The effectiveness of the neuraminidase enzymes in cleaving
terminal sialic acid residues was assessed in parallel with an
agglutination assay involving a lectin from L. polyphemus
(which binds sialic acid residues specifically). The lectin agglu-
tinated untreated RD, HeLa, and HeLa CD41 cells at a con-
centration of 10 to 20 mg/ml, compared with .100 mg/ml after
treatment of the cells with bacterial neuraminidase. This indi-
FIG. 2. LAV-2/B cell-free virus titer determinations on human CD4-negative
and HeLa CD41 cell lines pretreated with glycosylation inhibitors. The titers
(focus-forming units [ffu] per milliliter) are arithmetic means and standard de-
viations for triplicate parallel samples on cells treated with 0.1 mg of tunicamycin
per ml (u), 0.1 mM swainsonine (p), or 1 mM 1-deoxymannojirimycin (f) or
untreated (h).
TABLE 1. Infection and syncitium induction on tunicamycin-
pretreated human cells by LAV-2/B
Human cell line Titer (FFU/ml) % of infected cellsforming syncytia
HeLa CD41 7.5 3 103 50–75
RD 3.3 3 104 .90
HeLa 2.8 3 104 #1
HOS 2.4 3 103 #1
Rsb 1.6 3 103 0
Heb7a 3.6 3 104 0
HT-29 1.7 3 103 0
SCL1 0 0
WI38 0 0
HT1080 0 0
Six nonprimate cell linesa 0 0
aMv-1-lu, CCC, HSN, a23, SIRC, and NIH 3T3.
TABLE 2. Comparison of the titer of CBL-22 (HIV-2) on
untreated human cells and tunicamycin-treated human cells
Cell line
Titer of CBL-22 (FFU/ml) on:
Untreated cells Treated cells
RD 1.6 3 103 5.2 3 104
HeLa CD4 3.4 3 103 4.6 3 103
HeLa 2.0 3 102 1.6 3 102
Heb7a 4.0 3 101 6.0 3 101
Rsb 4.0 3 101 4.0 3 101
HOS, HT29, SCL1, WI38,
and HT1080
0 0
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cates that a significant proportion of the terminal sialic acid
residues have been cleaved under the conditions used.
Treatment of cells with protease decreases the apparent
titer of LAV-2/B by up to 10-fold. The biochemical nature of
the LAV-2/B-binding moiety on CD4-negative cells was fur-
ther characterized by incubation of RD cells with several pro-
teases (Fig. 5b). Following proteolytic cleavage of membrane
proteins, the proteases were inactivated with an excess of in-
hibitor and the cells were washed extensively. Trypsin-, a-chy-
motrypsin-, and bromelain-treated cells were infected 65, 80,
and 90% less, respectively, than control cells were. This indi-
cates that a cell surface protein is an essential component of
the CD4-independent HIV-2 binding or fusion process. Pro-
tease-treated HeLa CD41 cells showed a similar reduction (70
to 92%) in infection by LAV-2/B (results not shown).
The viability of the virus after incubation with protease-
treated cells was tested by replating the virus on untreated
cells. The titer of residual LAV-2/B remained the same (Fig.
5b, panel B) after incubation with either protease-treated or
mock-treated cells, indicating that all traces of protease had
been removed by the use of inhibitors and extensive washes.
The viability of cells after protease treatment was addressed
by digesting cell surface proteins after virus entry. The titer of
LAV-2/B on RD cells was identical after protease treatment or
mock treatment of the cells 5 h after addition of virus (results
not shown).
DISCUSSION
It was reported previously that HIV-2 LAV-2/B can infect
RD cells via a CD4-independent pathway (9). We have at-
tempted to characterize the cell surface receptor responsible
by several biochemical methods. Treatment of a variety of
human cells (Fig. 2) with the glycosylation inhibitor tunicamy-
FIG. 3. sCD4 sensitivity of HIV-2 cell-free virus titer determinations on RD (TE671) and HeLa CD41 cells. Cells were pretreated with tunicamycin (0.1 mg/ml)
for 24 h. HIV-2 was preincubated with sCD4 (10 mg/ml) for 1 h prior to infection of cells. (a) LAV-2/B infection of RD (TE671) cells. (b) LAV-2/B infection of HeLa
CD41 cells. (c) LAV-2ROD infection of RD (TE671) cells. (d) LAV-2ROD infection of HeLa CD41 cells. Titers (focus-forming units [ffu] per milliliter) are expressed
as arithmetic means and standard deviations for triplicate samples.
FIG. 4. Antibody sensitivity of LAV-2/B cell-free virus titer determinations
on RD, HeLa, or HeLa CD41 cells. Cells were pretreated with tunicamycin (0.1
mg/ml) and/or anti-CD4 (5 mg/ml) for 24 h prior to virus titer determinations.
LAV-2/B was neutralized for 1 h with anti-LAV-2/B (8e) prior to titer determi-
nations on cells. Titers (focus-forming units [ffu] per milliliter) are expressed as
arithmetic means and standard deviations for triplicate samples. Symbols: h, no
antibody; p, anti-LAV-2/B 8e; f, anti-CD4.
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cin, swainsonine, or 1-deoxymannojirimycin results in a signif-
icant increase in the apparent titer of LAV-2/B. This increase
in infectibility appears to be specific to the HIV-2 interaction
with the CD4-independent receptor, since tunicamycin does
not promote infection of some other human (WI38, SCL1, and
HT1080) and nonprimate (NIH 3T3, HSN, CCC, Mv-1-lu, a23,
and SIRC) cells (Table 1). This is most probably due to the
nonexpression of the CD4-independent receptor on these cell
types, since HIV-2 is able to infect and replicate in some of
these cells when they express human CD4 on the cell surface
(6, 29). The infection of RD cells by a different HIV-2 strain
(CBL-22) was enhanced 30-fold after treatment of the cells
with tunicamycin (Table 2). This demonstrates that although
infection of cells by the CD4-independent route is most effi-
cient with LAV-2/B, other strains of HIV-2 are also capable of
infecting CD4 negative cells. Several other cell lines (Table 2),
however, had a very low rate of infection or were uninfected by
CBL-22, even after treatment with tunicamycin.
The removal of the block to infection of certain human cell
lines by inhibitors of complex glycan synthesis may go some
way toward explaining the observed cell tropism pattern of
LAV-2/B. The endogenous receptors for LAV-2/B on these
cell types are nonfunctional but become functional after treat-
ment of the cells with glycosylation inhibitors. One possibility
is that these receptors are rendered nonfunctional by addition
of sugar residues during synthesis that block virus binding or
internalization. The LAV-2/B envelope must interact with the
polypeptide backbone of the receptor, with the site of interac-
tion becoming more or less blocked by complex glycan struc-
tures depending on the variation in glycosylation patterns in
different cells. The putative interaction with the polypeptide
rather than the sugar moiety of the receptor is emphasized by
the varying increase in infection of human cells when treated
with tunicamycin compared with 1-deoxymannojirimycin and
swainsonine. Treatment of cells with tunicamycin blocks all
N-linked glycosylation, since it inhibits the synthesis of the
high-mannose lipid-linked core glycan to which complex car-
bohydrate structures are added subsequently (44). This would
leave the polypeptide backbone fully exposed for interaction
with the LAV-2/B envelope. Swainsonine and 1-deoxyman-
nojirimycin, on the other hand, inhibit mannose-trimming en-
zymes (mannosidase II and IA/B respectively) and therefore
block the conversion of high-mannose to complex oligosaccha-
ride-type structures (18). This would result in glycoproteins
with truncated high-mannose carbohydrates capable of par-
tially blocking the interaction of LAV-2/B envelope with the
receptor; this explains the lower increase in the apparent titer
of LAV-2/B on cells treated with these two antibiotics.
It has been reported previously that tunicamycin treatment
of CEM cells leads to a down regulation of surface expression
of CD4 molecules (26). This was shown to be due to the
preferential intracellular degradation of the unglycosylated
precursor. In the same study, Konig et al. (26) did not observe
any inhibition of surface expression of three other membrane
glycoproteins (namely, CD2, CD5, and the human transferrin
receptor) after treatment of cells with tunicamycin. Other
groups have noted that tunicamycin prevents some but not all
glycoproteins from being secreted or reaching the cell surface
(32, 34, 35, 42). Another possible explanation, therefore, for
the increase in the titer of LAV-2/B on CD4-negative cells
treated with tunicamycin is that we are observing a down reg-
ulation in the membrane expression of a glycoprotein which
normally inhibits HIV-2 entry into CD4-negative cells. We
have ruled out the possibility of a soluble factor which acts to
inhibit LAV-2/B infection by pretreating cells or virus with
HeLa cell conditioned medium. The presence of a membrane-
bound inhibitory protein would also seem unlikely, since both
swainsonine and 1-deoxymannojirimycin also increase the in-
fectibility of CD4-negative cells by LAV-2/B; neither of these
antibiotics has been shown to significantly affect the surface
expression of glycoproteins (18).
HIV-2 infection of tunicamycin-treated RD cells was further
enhanced in the presence of sCD4 (Fig. 3). This was more
dramatically illustrated with HIV-2 LAV-2ROD than with
LAV-2/B, since LAV-2ROD normally shows only a limited in-
fection of RD cells. Previous studies have shown that sCD4
enhances HIV-2 and SIV infection of CD4-negative cells (9).
Binding of sCD4 to HIV-1 gp120 results in conformational
changes which alter the exposure of the V3 loop to binding of
V3 antibodies (41). We could speculate that the enhancement
of HIV-2 infection of CD4-negative cells is due to the inter-
action of sCD4 with a homologous V3 region, resulting in the
exposure of a buried site on gp110 for receptor binding. It is
therefore probable that this receptor-binding site is already
FIG. 5. Neuraminidase and protease sensitivity of LAV-2/B infection of RD,
HeLa, and HeLa CD41 cells. (a) Cells were pretreated with neuraminidase from
S. typhimurium (f) or V. cholerae (p) or cPBS–0.05% FCS alone (h), washed,
and subsequently infected with LAV-2/B for 2 h at 48C. Titers (focus-forming
units [ffu] per milliliter) are expressed as arithmetic means and standard devia-
tions for triplicate samples. (b) In panel A, RD cells were incubated for 10 min
at 378C in cPBS–0.1% EDTA alone (h) or with trypsin (1 mg/ml [u]), a-chy-
motrypsin (0.02 mg/ml [p]), or bromelain (0.02 mg/ml [f]), all diluted in cPBS–
0.1% EDTA, washed, and subsequently infected with LAV-2/B for 2 h at 48C. In
panel B, the relative infection of RD cells by residual unbound virus remaining
after incubation with untreated and protease-treated cells (cPBS/0.1% EDTA
alone [h]; trypsin [u]; a-chymotrypsin [p]; bromelain [f]) is shown. Values in
both panels represent arithmetic means and standard deviations for triplicate
samples, expressed as percentages of values obtained from infected control cells.
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exposed on LAV-2/B envelope protein, since significant infec-
tion of CD4-negative cells is observed in the absence of sCD4.
The observation that sCD4 inhibits the entry of HIV-2 into
HeLa CD4 cells provides further evidence that the HIV-2
envelope interacts with the CD4-independent receptor via a
site distinct from the site which binds to CD4.
Treatment of RD cells with two different bacterial neuramin-
idases with preferences for different terminal sialic acid link-
ages (neuraminidase from V. cholerae preferentially cleaves
a-2,6-linked sialic acid residues, and neuraminidase from S.
typhimurium preferentially cleaves a-2,3-linked sialic acid res-
idues) had no significant effect on subsequent infection of RD,
HeLa, or HeLa CD41 cells by LAV-2/B. It has been shown
that terminal sialic acid residues are required for the attach-
ment of members of the polyomavirus genus to host cells, with
a preference for either a-2,6- or a-2,3-linked sialic acid resi-
dues (4, 17, 21). The fact that removal of terminal sialic acid
residues from membrane glycoproteins had no effect on bind-
ing and infection of LAV-2/B suggests that charge repulsion
does not play a role in preventing entry by LAV-2/B into some
CD4-negative cells.
The protease sensitivity of HIV-2 attachment and/or entry
into CD4-negative cells indicates the involvement of a mem-
brane protein in the binding or fusion event. Furthermore, the
enhancement of infection when cells are treated with glycosy-
lation inhibitors suggests that this membrane protein is usually
glycosylated to different degrees, depending on the cell type.
Harouse et al. (19) have identified a galactocerebroside on
CD4-negative neural cells to which gp120 of HIV-1 binds spe-
cifically and with high affinity, suggesting a role in HIV entry
into neural cells. Two HIV-1 gp120-binding proteins have been
identified by Berberian et al. (3) (immunoglogulin VH3 gene
products) and Curtis et al. (14) (membrane-associated C-type
lectin), although neither of these proteins promoted HIV in-
ternalization into cells. It is therefore debatable whether these
proteins play any significant role in CD4-independent infection
of cells by LAV-2/B. The putative CD4-independent receptor
for HIV-2 described here appears to consist of at least one
membrane-associated glycoprotein, although we cannot rule
out the possibility of other membrane molecules playing an
additional role in either binding or fusion.
It is not clear whether the CD4-independent infection of
certain human cells by HIV-2 has significant in vivo implica-
tions. There is limited evidence of HIV-1 infection of gut or
brain cells, other than those of hematopoietic origin, in vivo (5,
25, 33, 36). However, it is not yet evident whether infection of
cell lines in vitro is relevant to tissue-specific pathogenesis,
such as enteropathy and dementia, in AIDS. The experiments
reported here and previously (9) have been restricted to the
interaction of established laboratory strains of HIV-2 with
immortalized CD4-negative cell lines. The results presented by
Harouse et al. (19, 20) suggest that galactocerebroside could
serve as a receptor for the infection of oligodendrocytes, which
were noted to be infected in one study of brain biopsy speci-
mens (47). The putative CD4-independent glycoprotein recep-
tor described here may play a related or additional role in
HIV-2 entry into CD4 negative cells in vivo. Further investi-
gations involving HIV-2 infection of primary-cell cultures and
tissue tropism, comparing LAV-2ROD with LAV-2/B, could be
considered.
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